Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.69 |
| ▸ | CA1 | P00915 | 4/20 | 0.69 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.68 |
| ▸ | CTSL | P07711 | 1/20 | 0.67 |
| ▸ | ACE | P12821 | 3/20 | 0.64 |
| ▸ | MME | P08473 | 1/20 | 0.60 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.57 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3404637 | 1.00 | CA2 (0.69) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL5793343 | 1.00 | CA2 (0.69) | CA2CA1PTPN1CTSLACE | |
| Alcohol SCHEMBL19231109 | 0.94 | CTSL (0.65) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL3497780 | 0.94 | PTPN1 (0.72) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL8520566 | 0.94 | PTPN1 (0.72) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL4054766 | 0.94 | CA2 (0.77) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL4054764 | 0.94 | CA2 (0.77) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL8671997 | 0.94 | CA2 (0.77) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL13669589 | 0.93 | CTSL (0.67) | CA2CA1PTPN1CTSLACE | |
| SCHEMBL4369236 | 0.93 | CTSL (0.67) | CA2CA1PTPN1CTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5767158-A | FOR BLEACHING SKIN | SHISEIDO CO., LTD. (JP) | 1998-06-16 | — | — | US | claimed |
| WO-2020216240-A1 | DICYCLIC ALKANE COMPOUND USEFUL AS INHIBITOR OF PLASMA KALLIKREIN | 南京明德新药研发有限公司 | 2020-10-29 | — | — | WO | disclosed |
| EP-2409569-B1 | Method for administering GLP-1 molecules | EMISPHERE TECH INC (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-1478233-B1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECH INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2409569-A2 | Method for administering GLP-1 molecules | Emisphere Technologies, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7939494-B2 | Method for administering GLP-1 molecules | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939494-B2 | Method for administering GLP-1 molecules | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-11-19 | — | — | US | disclosed |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-11-19 | — | — | US | disclosed |
| US-5767158-A | FOR BLEACHING SKIN | SHISEIDO CO., LTD. (JP) | 1998-06-16 | — | — | US | disclosed |
| EP-0728469-A2 | An endermic liniment | SHISEIDO COMPANY LIMITED (JP) | 1996-08-28 | — | — | EP | disclosed |
| US-5219731-A | Cleaving an oxazolone precursor with lipase | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1993-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | CA2 1611/4885CA1 2850/4885PTPN1 1737/4885 |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | CA2 1611/4885CA1 2850/4885PTPN1 1737/4885 |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | CA2 1611/4885CA1 2850/4885PTPN1 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.